Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy

Retina

Volumn 37, Issue 6, 2017, Pages 1084-1091

  Gergely, Róbert ^a   Kovács, Illés ^a   Schneider, Miklós ^a   Resch, Miklós ^a   Papp, András ^a   Récsán, Zsuzsanna ^a   Nagy, Zoltán Zsolt ^a   Ecsedy, Mónika ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

choroidal thickness; chronic central serous chorioretinopathy; mineralocorticoid receptor antagonist; pachychoroid pigment epitheliopathy; subretinal fluid

Indexed keywords

EPLERENONE; POTASSIUM; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BACKACHE; BEST CORRECTED VISUAL ACUITY; BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY; CENTRAL SEROUS RETINOPATHY; CHOROIDAL THICKNESS; CLINICAL ARTICLE; COMPARATIVE STUDY; CREATININE CLEARANCE; DISEASE DURATION; DIZZINESS; FEMALE; FOLLOW UP; HUMAN; MACULAR THICKNESS; MALE; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; PACHYCHOROID PIGMENT EPITHELIOPATHY; PIGMENT DISORDER; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; SOMNOLENCE; VISION; VISUAL ACUITY; XEROSTOMIA; ANALOGS AND DERIVATIVES; CHOROID; CHRONIC DISEASE; CLINICAL TRIAL; EXUDATE; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RETINA MACULA LUTEA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; CENTRAL SEROUS CHORIORETINOPATHY; CHOROID; CHRONIC DISEASE; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; MACULA LUTEA; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; SPIRONOLACTONE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84987625004     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001303     Document Type: Article

References (31)

1. Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008;115:169-173.
2. Liew G, Quin G, Gillies M, et al. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 2013;41:201-214.
3. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47: 431-448.
4. Quin G, Liew G, Ho IV, et al. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol 2013;41:187-200.
5. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011;22: 166-173.
6. Imamura Y, Fujiwara T, Margolis R, et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009;29:1469-1473.
7. Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015;48:82-118.
8. Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina 2013;33:1659-1672.
9. Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011;152:784-792.e782.
10. Lim JW, Kang SW, Kim YT, et al. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol 2011;95:514-517.
11. Wu ZH, Lai RY, Yip YW, et al. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 2011;31:1378-1386.
12. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288-298.
13. Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010;35:91-98.
14. Li XJ, Zhang JS. Intravitreal bevacizumab injection for chronic central serous chorioretinopathy. Chin Med J (Engl) 2010;123: 2145-2147.
15. Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2011;249:969-974.
16. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010;30:100-106.
17. Fine HF, Ober MD, Hariprasad SM. Current concepts in managing central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 2014;45:9-13.
18. Jirarattanasopa P, Ooto S, Tsujikawa A, et al. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 2012;119:1666-1678.
19. Nicholson B, Noble J, Forooghian F, et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013;58:103-126.
20. Zhao M, Celerier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012;122:2672-2679.
21. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J 2010;24: 3405-3415.
22. Danjuma MI, Mukherjee I, Makaronidis J, et al. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 2014;16:414.
23. Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2013;33:2096-2102.
24. Herold TR, Prause K, Wolf A, et al. Spironolactone in the treatment of central serous chorioretinopathy-a case series. Graefes Arch Clin Exp Ophthalmol 2014;252:1985-1991.
25. Ghadiali Q, Jung JJ, Yu S, et al. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina 2016;36:611-618.
26. Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 2014;16:414.
27. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-1321.
28. Fujimoto H, Gomi F, Wakabayashi T, et al. Morphologic changes in acute central serous chorioretinopathy evaluated by Fourier-domain optical coherence tomography. Ophthalmology 2008;115:1494-1500.
29. Ojima Y, Tsujikawa A, Yamashiro K, et al. Restoration of outer segments of foveal photoreceptors after resolution of central serous chorioretinopathy. Jpn J Ophthalmol 2010;54: 55-60.
30. Boonarpha N, Zheng Y, Stangos AN, et al. Standardization of choroidal thickness measurements using enhanced depth imaging optical coherence tomography. Int J Ophthalmol 2015;8: 484-491.
31. Ikuno Y, Maruko I, Yasuno Y, et al. Reproducibility of retinal and choroidal thickness measurements in enhanced depth imaging and high-penetration optical coherence tomography. Invest Ophthalmol Vis Sci 2011;52:5536-5540.